LUC00036I1 - - Google Patents
Info
- Publication number
- LUC00036I1 LUC00036I1 LU00036C LUC00036C LUC00036I1 LU C00036 I1 LUC00036 I1 LU C00036I1 LU 00036 C LU00036 C LU 00036C LU C00036 C LUC00036 C LU C00036C LU C00036 I1 LUC00036 I1 LU C00036I1
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LUC00036I1 true LUC00036I1 (OSRAM) | 2017-10-02 |
| LUC00036I2 LUC00036I2 (OSRAM) | 2017-12-01 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00036C LUC00036I2 (OSRAM) | 2005-01-26 | 2017-09-29 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (OSRAM) |
| JP (1) | JP5576591B2 (OSRAM) |
| KR (1) | KR101468216B1 (OSRAM) |
| AU (1) | AU2006209547C1 (OSRAM) |
| BE (1) | BE2017C028I2 (OSRAM) |
| CA (1) | CA2594713A1 (OSRAM) |
| CY (2) | CY1119393T1 (OSRAM) |
| DK (1) | DK1849470T4 (OSRAM) |
| ES (1) | ES2630002T5 (OSRAM) |
| FI (1) | FI1849470T4 (OSRAM) |
| FR (1) | FR17C1028I2 (OSRAM) |
| HU (2) | HUE033306T2 (OSRAM) |
| LT (2) | LT1849470T (OSRAM) |
| LU (1) | LUC00036I2 (OSRAM) |
| NL (1) | NL300889I2 (OSRAM) |
| PL (1) | PL1849470T5 (OSRAM) |
| PT (1) | PT1849470T (OSRAM) |
| RU (1) | RU2394581C2 (OSRAM) |
| SI (1) | SI1849470T2 (OSRAM) |
| TW (1) | TWI362265B (OSRAM) |
| WO (1) | WO2006080327A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| ES2630002T5 (es) | 2005-01-26 | 2024-09-19 | Taiho Pharmaceutical Co Ltd | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| PL2148676T3 (pl) * | 2007-04-25 | 2016-12-30 | Stosowanie sapacytabiny do leczenia choroby proliferacyjnej | |
| KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
| PL2273983T3 (pl) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego |
| EP2303283A2 (en) * | 2008-05-15 | 2011-04-06 | Katholieke Universiteit Leuven K.U. Leuven R&D | Anti-cancer combination therapy |
| PE20120631A1 (es) | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion |
| PE20121067A1 (es) | 2009-07-22 | 2012-09-05 | Gruenenthal Chemie | Forma de dosificacion de liberacion controlada extruida por fusion en caliente |
| ES2486791T3 (es) | 2010-09-02 | 2014-08-19 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende una sal inorgánica |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| SI2736495T1 (sl) | 2011-07-29 | 2017-12-29 | Gruenenthal Gmbh | Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila |
| PE20141650A1 (es) | 2011-07-29 | 2014-11-22 | Gruenenthal Chemie | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
| AU2012295841B2 (en) * | 2011-08-16 | 2015-12-10 | Les Laboratoires Servier | Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| EP2829611A4 (en) | 2012-03-14 | 2015-12-02 | Nisshin Pharma Inc | SULFURAMINOUS-SUSTAINABLE COMPOSITION |
| RS57913B1 (sr) | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| SG11201406550QA (en) * | 2012-05-16 | 2014-11-27 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| HUE041687T2 (hu) * | 2013-03-27 | 2019-05-28 | Taiho Pharmaceutical Co Ltd | Antitumor szer, amely tartalmaz kis dózisú irinotekan-hidroklorid-hidrát-ot |
| LT2979701T (lt) * | 2013-03-27 | 2020-11-10 | Taiho Pharmaceutical Co., Ltd. | Priešnavikinis agentas, įskaitant irinotekano hidrochlorido hidratą |
| JP6312660B2 (ja) * | 2013-05-17 | 2018-04-18 | 大鵬薬品工業株式会社 | Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法 |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| UA121538C2 (uk) | 2013-09-06 | 2020-06-25 | Тайхо Фармасьютікал Ко., Лтд. | Спосіб лікування злоякісного новоутворення |
| AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
| EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| JP6871868B2 (ja) * | 2016-01-08 | 2021-05-19 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| WO2017135412A1 (ja) | 2016-02-05 | 2017-08-10 | 大鵬薬品工業株式会社 | 重度腎機能障害を有する癌患者に対する治療方法 |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100424934B1 (ko) | 1995-03-29 | 2004-07-27 | 다이호야쿠힌고교 가부시키가이샤 | 우라실유도체및이를함유하는항종양효과증강제및항종양제 |
| CA2238331C (en) * | 1996-09-24 | 2003-02-25 | Taiho Pharmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| ES2630002T5 (es) | 2005-01-26 | 2024-09-19 | Taiho Pharmaceutical Co Ltd | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
-
2006
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es active Active
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en active Active
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en active Active
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja active Active
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko active Active
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE2021C524I2 (OSRAM) | ||
| BE2021C519I2 (OSRAM) | ||
| BE2020C508I2 (OSRAM) | ||
| FR16C0018I1 (OSRAM) | ||
| IN2014DN07705A (OSRAM) | ||
| BRPI0601358B8 (pt) | Aplicador de clipe cirúrgico | |
| BRPI0601402B8 (pt) | Aplicador de grampos cirúrgicos | |
| BR122017004707A2 (OSRAM) | ||
| BRPI0609157A8 (OSRAM) | ||
| BRPI0608519A2 (OSRAM) | ||
| BR122020005056A2 (OSRAM) | ||
| BR122016029989A2 (OSRAM) | ||
| JP2006201293A5 (OSRAM) | ||
| BRPI0604219A (OSRAM) | ||
| JP2006250587A5 (OSRAM) | ||
| IN241255B (OSRAM) | ||
| BRPI0618215B8 (OSRAM) | ||
| JP2006239057A5 (OSRAM) | ||
| BY2237U (OSRAM) | ||
| CN105122969C (OSRAM) | ||
| CN300742029S (zh) | 洗衣机 | |
| CN300726001S (zh) | 鞋帮 | |
| CN300725997S (zh) | 鞋帮 | |
| CN300725996S (zh) | 鞋帮 | |
| CN300725995S (zh) | 鞋帮 |